This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Humana (HUM) Closes $2.8B Kindred Hospice Divestment to CD&R
by Zacks Equity Research
Humana (HUM) retaining the remaining 40% stake will likely enable it to gain from the standalone company's long-term success.
Select Medical (SEM) Shares Dip on Q2 Earnings & Revenue Miss
by Zacks Equity Research
Select Medical's (SEM) second-quarter earnings take a hit from escalating expenses and reduced admissions within the Critical Illness Recovery Hospital segment.
Acadia Healthcare (ACHC) Stock Up 3% on Q2 Earnings Beat
by Zacks Equity Research
Acadia Healthcare's (ACHC) second-quarter results benefit from a strong-performing U.S. business. A raised 2022 guidance with respect to EPS bodes well.
If You Invested $1000 in Centene a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Cigna (CI) Q2 Earnings Beat Estimates, Hikes '22 EPS View
by Zacks Equity Research
Cigna's (CI) second-quarter results indicate solid membership growth plus sound contributions from Evernorth and Cigna Healthcare segments. An upped 2022 EPS outlook remains noteworthy.
Zacks Investment Ideas feature highlights: Humana and Centene
by Zacks Equity Research
Humana and Centene are part of Zacks Investment Ideas article.
Stick With These Health Care Leaders in the Second Half of 2022
by Bryan Hayes
There are steps we can take to mitigate the volatility and benefit our portfolio as we move further into the second half of the year.
Top Analyst Reports for Novartis, Duke Energy & Boston Scientific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Duke Energy Corporation (DUK), and Boston Scientific Corporation (BSX).
Molina Healthcare (MOH) Q2 Earnings Beat, Hikes '22 EPS View
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results gain from membership growth within its Medicaid and Medicare lines of business. A hiked adjusted EPS guidance for 2022 is noteworthy.
Centene (CNC) Q2 Earnings Beat Estimates, Boosts 2022 View
by Zacks Equity Research
Centene (CNC) currently has $3.4 billion remaining in its share buyback program.
Centene (CNC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 2.31% and 1.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Gears Up for Q2 Earnings: What Lies Ahead?
by Zacks Equity Research
Centene's (CNC) second-quarter results are likely to reflect growth in premiums.
The Zacks Analyst Blog Highlights Visa, Abbott Laboratories, Salesforce, Wells Fargo and Centene
by Zacks Equity Research
Visa, Abbott Laboratories, Salesforce, Wells Fargo and Centene are included in this Analyst Blog.
Top Research Reports for Visa, Abbott & Salesforce
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Abbott Laboratories (ABT) and Salesforce, Inc. (CRM).
Molina (MOH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Much a $1000 Investment in Centene Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Centene (CNC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Centene (CNC) closed at $91.35, marking a +1.82% move from the previous day.
What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results are likely to benefit from better patient volumes. The results might partly suffer from escalating labor costs that might dampen bottom line growth.
Centene (CNC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Centene (CNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.
Centene (CNC) Divests Unit to Boost Focus on Core Business
by Zacks Equity Research
Centene (CNC) closes the deal to divest its pharmacy business. CNC primarily intends to pursue share repurchases with proceeds received from the transaction.
UnitedHealth Group (UNH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 6.30% and 0.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Wins Contract to Serve Delaware's Medicaid Members
by Zacks Equity Research
Centene's (CNC) Delaware subsidiary receives a contract from the State of Delaware's DHSS to efficiently serve the diversified health needs of the state's Medicaid members.
HUM or CNC: Which Stock is Better-Positioned at the Moment?
by Zacks Equity Research
Humana (HUM) and Centene (CNC) are poised to grow in the promising HMO space. We try to find out which one fares better via comparative evaluation.
UnitedHealth (UNH) to Post Q2 Earnings: What to Expect?
by Zacks Equity Research
UnitedHealth Group's (UNH) second-quarter results are likely to reflect improving premiums, products and higher expenses.